Get the Stockscreener App
14.86
0.54%
-0.08
Pre-market:
14.71
-0.15
-1.01%
Biohaven Ltd stock is traded at $14.86, with a volume of 1.31M.
It is down -0.54% in the last 24 hours and up +22.41% over the past month.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
See More
Previous Close:
$14.94
Open:
$14.94
24h Volume:
1.31M
Relative Volume:
0.47
Market Cap:
$2.24B
Revenue:
-
Net Income/Loss:
$-647.68M
P/E Ratio:
-2.6208
EPS:
-5.67
Net Cash Flow:
$-594.49M
1W Performance:
-10.70%
1M Performance:
+22.41%
6M Performance:
+24.66%
1Y Performance:
+12.07%
1-Day Range:
$14.56
$14.98
1-Week Range:
$14.56
$17.28
52-Week Range:
$7.48
$18.57
Biohaven Ltd Stock (BHVN) Company Profile
Name
Biohaven Ltd
Sector
Industry
Phone
203-404-0410
Address
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
14.86 | 2.28B | 0 | -647.68M | -594.49M | -5.67 |
VRTX
Vertex Pharmaceuticals Inc
|
477.08 | 121.89B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.45 | 69.52B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
862.93 | 54.49B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
184.44 | 39.11B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
279.14 | 38.46B | 4.29B | 577.22M | 641.34M | 4.2086 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | Canaccord Genuity | Buy |
| Feb-06-26 | Initiated | Goldman | Buy |
| Jan-21-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-03-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-26-25 | Downgrade | UBS | Buy → Neutral |
| Nov-06-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Nov-05-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-17-25 | Initiated | Citigroup | Buy |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| May-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Sep-16-24 | Initiated | Jefferies | Buy |
| Sep-04-24 | Initiated | Bernstein | Outperform |
| Jul-24-24 | Initiated | Morgan Stanley | Overweight |
| Feb-16-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Dec-22-23 | Initiated | H.C. Wainwright | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Jan-24-23 | Initiated | SVB Securities | Outperform |
| Jan-04-23 | Initiated | JP Morgan | Overweight |
| Dec-02-22 | Initiated | BTIG Research | Buy |
| Oct-26-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-12-22 | Initiated | Piper Sandler | Overweight |
| Aug-19-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-08-22 | Downgrade | Wedbush | Outperform → Neutral |
| May-11-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-21 | Downgrade | UBS | Buy → Neutral |
| Aug-03-21 | Reiterated | Canaccord Genuity | Buy |
| Mar-11-21 | Initiated | UBS | Buy |
| Dec-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-17-20 | Initiated | Cowen | Outperform |
| Feb-10-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Nov-22-19 | Initiated | Wedbush | Outperform |
| Jun-25-19 | Reiterated | Canaccord Genuity | Buy |
| May-06-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-19 | Reiterated | Needham | Buy |
| Jul-03-18 | Reiterated | Needham | Buy |
| Jul-02-18 | Reiterated | Needham | Buy |
| Apr-05-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-22-18 | Reiterated | Canaccord Genuity | Buy |
| Dec-15-17 | Initiated | Canaccord Genuity | Buy |
| Oct-03-17 | Reiterated | Needham | Buy |
View All
Biohaven Ltd Stock (BHVN) Latest News
Price to earnings forward of Biohaven Ltd. – BOATS:BHVN - TradingView
Biohaven Research Ltd Shs Unsponsored Brazilian Depositary Receipt Repr 0.33333333 Shs - TradingView
Biohaven: Nice Pipeline Momentum, But Its Runway Is A Risk (NYSE:BHVN) - Seeking Alpha
Enterprise value to EBIT forward of Biohaven Ltd. – BOATS:BHVN - TradingView
Price to sales forward of Biohaven Ltd. – NYSE:BHVN - TradingView
Price to sales forward of Biohaven Ltd. – BOATS:BHVN - TradingView
Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Co - GuruFocus
Biohaven (BHVN) Advances Key Trials Following Pipeline Progress While Valuation Still Looks Pricey - Sahm
Enterprise value to revenue forward of Biohaven Ltd. – NYSE:BHVN - TradingView
BHVN News | BIOHAVEN LTD (NYSE:BHVN) - ChartMill
Biohaven announces leadership changes - Hartford Business Journal
Biohaven Announces Scientific Leadership Changes - Contract Pharma
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership - Yahoo Finance
Biohaven (BHVN) Insider Trading Activity 2026 - MarketBeat
Is Biohaven’s (BHVN) R&D Shake-Up Quietly Redefining Its Late-Stage Pipeline Strategy? - Yahoo Finance
Biohaven Announces Scientific Leadership Transitions - GuruFocus
Biohaven Chief Scientific Officer Bruce Car to Transition to Chief Innovation Officer - Moomoo
Biohaven: Bruce Car, Transitioning From Chief Scientific Officer to Chief Innovation Officer Focusing on External Collaborations >BHVN - Moomoo
Biohaven Announces Leadership Changes to Accelerate CNS Drug Discovery and Innovation Through Bexorg Collaboration – Minichart - Minichart
Biohaven announces leadership changes in discovery unit By Investing.com - Investing.com India
Biohaven announces leadership changes in discovery unit - Investing.com
Biohaven (NYSE: BHVN) shifts CSO to innovation role, promotes discovery head - Stock Titan
Press Release: Biohaven Announces Scientific Leadership Transitions - Moomoo
Biohaven (BHVN) Completes Enrollment in RISE3 Trial - Yahoo Finance
Biohaven (BHVN) Is Up 5.6% After Advancing Two Late-Stage Trials in Epilepsy and Graves’ Disease - Sahm
BHVN Stock Builds Momentum Ahead Of Multiple H2 2026 Clinical Data Readouts - Yahoo Finance
Janus Henderson holds 8.58M Biohaven shares (BHVN) — 5.7% stake - Stock Titan
10 Best Performing American Stocks in June 2026 - Insider Monkey
Why Wall Street Is Growing More Cautious on Biohaven (BHVN) - Insider Monkey
Discipline and Rules-Based Execution in BHVN Response - Stock Traders Daily
BHVNBiohaven Ltd Latest SEC Filings - Finviz
Biohaven Shares Drop 9.8% to $14.28 - Intellectia AI
Does Advancing Opakalim and BHV-1300 to Pivotal Trials Change The Bull Case For Biohaven (BHVN)? - simplywall.st
J.P. Morgan Maintains Biohaven(BHVN.US) With Buy Rating - Moomoo
Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out - Sahm
Biohaven completes enrollment in opakalim epilepsy trial - Investing.com
BHVN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Biohaven completes enrollment in opakalim epilepsy trial By Investing.com - Investing.com Nigeria
Biohaven completes enrollment in focal epilepsy drug trial - StreetInsider
Biohaven's epilepsy drug Opakalim finishes pivotal study enrollment - Stock Titan
Biohaven Shares Down as Phase 3 Trial Concerns Trigger Downgrade at BofA - Moomoo
What's Going On With Biohaven Stock Monday?Biohaven (NYSE:BHVN) - Benzinga
Biohaven (BHVN) Shares Decline Nearly 10% Amid Market Fluctuatio - GuruFocus
BHVN Downgraded by B of A Securities -- Price Target Lowered to $11 - GuruFocus
Biohaven begins phase 3 trial of BHV-1300 for Graves’ disease - Investing.com
BofA downgrades Biohaven stock on epilepsy drug concerns By Investing.com - Investing.com Nigeria
BofA Securities Downgrades Biohaven to Underperform From Neutral, Trims Price Target to $11 From $12 - marketscreener.com
Biohaven Doses First Patient in Phase 3 Trial of BHV-1300 for Graves' Disease - marketscreener.com
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session - Benzinga
Update: BofA Securities Downgrades Biohaven to Underperform From Neutral, Trims Price Target to $11 From $12 - Moomoo
BofA Securities Downgrades Biohaven to Underperform From Neutral, $11 Price Target - Moomoo
Biohaven Ltd Stock (BHVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
1.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):